US Patent Office Granted Can-Fite Namodenoson Patent for Use as anti-Obesity Drug
The Namodenoson oral drug is well positioned in the field of anti-obesity agents due to its activity and favorable safety ...
IPWatchdog19h
CAFC Declines to Declare RDOE Subsumed by 1952 Patent Act Despite ‘Compelling’ Arguments
On January 25, the U.S. Court of Appeals for the Federal Circuit (CAFC) issued a precedential decision in Steuben Foods, Inc.